Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
252
resultados
Última actualización
27/01/2026 [06:53:00]
Resultados 150 a 175 de 252
Resumen de: US20260014076A1
A preparation of PEGylated solid lipid core nanocarriers (SLN) is loaded with at least one drug for delivery to a subject. SLNs having a small size, neutral charge, and high drug encapsulation efficiency are formed. PEGylation improves SLN permeability without hindering cellular uptake, particularly permeability of nasal mucous for intranasal delivery. PEGylated SLNs are suitable for intranasal, inhaled, oral or injected drug delivery. Exemplary formulations include a combined antiretroviral therapy (cART) designed to cross the blood-brain barrier and treat neuroAIDS.
Resumen de: WO2026015458A1
The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising an antigen-recognizing receptor (e.g., a HIT receptor) and an inhibitory polynucleotide. These cells have improved activity and/or efficiency.
Resumen de: WO2026015822A1
A cationic lipid, a lipid nanoparticle containing the cationic lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject.
Resumen de: WO2026015831A1
A cationic lipid, a lipid nanoparticle containing the cationic lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject.
Resumen de: US20260014077A1
Disclosed are nanoparticle preparations including a nucleic acid agent, a nucleic acid carrier, a metal salt, a polyethylene glycol (PEG)-lipid, a phospholipid, and a cholesterol or its derivative. Also provided are preparation methods and methods for treating or preventing a condition in a subject using such a nanoparticle preparation.
Resumen de: WO2026015812A1
Labelled DNA Origami for selective imaging of KRAS-mutant pancreatic cancer cells in a desmoplastic pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) are disclosed, as well as DNA Origami nanocomplexes for targeted delivery of a therapeutic payload to KRAS-mutant pancreatic cancer cells in a subject.
Resumen de: WO2026015741A1
A hybrid nanomaterial for coral recruitment includes silica nanoparticles that encapsulate exometabolites and a hydrogel matrix comprising a photopolymerizable material. The silica nanoparticles and the hydrogel matrix are combined to form a nanoink coating for crosslinking on a substrate that can be retained in a reef framework in natural seawater. The hybrid nanomaterial mimics the biochemical attractants, i.e., the "smell," of healthy reefs, thereby enhancing coral recruitment.
Resumen de: WO2026015713A1
The present application is directed, in general, to tolerizing immune modifying particles comprising antigens for use in treating alpha-gal syndrome, for example αGal containing proteins.
Resumen de: WO2026012450A1
Provided are a method for introducing a target nucleic acid sequence into a primary cell, and a nucleic acid-lipid nanoparticle composition encapsulating a linear DNA. The target nucleic acid sequence is inserted into the genome of the primary cell and/or expressed in the primary cell. The method comprises contacting the primary cell with the nucleic acid-lipid nanoparticle composition encapsulating the linear DNA.
Resumen de: WO2026012294A1
Provided are a drug, a method, and use for treating diseases caused by autoantibody production resulting from excessive proliferation of B cells. The drug for treating diseases caused by autoantibody production resulting from excessive proliferation of B cells comprises: an mRNA encoding a chimeric antigen receptor molecule and a T cell targeting lipid nanoparticle. The drug can produce a chimeric antigen receptor T cell in vivo. The lipid nanoparticle comprises: a cationic lipid, a phospholipid, cholesterol, a PEG lipid, and a targeting molecule. The targeting molecule mediates T cell targeting. The lipid nanoparticle encapsulating the mRNA of the chimeric antigen receptor molecule (mRNA-LNP) is used to deliver the mRNA into a T cell in vivo to produce the chimeric antigen receptor T cell, and pathological autoreactive B cells are eliminated to achieve the treatment of diseases caused by autoantibody production resulting from excessive proliferation of B cells.
Resumen de: AU2024307171A1
A pharmaceutical composition containing a cationic lipid and the use thereof. Specifically, provided are a pharmaceutical composition comprising a carrier, the carrier comprising a cationic lipid, and the molar percentage of the cationic lipid to the carrier being greater than or equal to 10% and less than 50%.
Resumen de: WO2026015717A1
Disclosed are nanoparticle preparations including a nucleic acid agent, a nucleic acid carrier, a metal salt, a polyethylene glycol (PEG)-lipid, a phospholipid, and a cholesterol or its derivative. Also provided are preparation methods and methods for treating or preventing a condition in a subject using such a nanoparticle preparation.
Resumen de: AU2024303275A1
Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.
Resumen de: AU2024288835A1
The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier wherein the lipase or a fragment thereof is in the open conformation, a protease or a fragment thereof immobilized on the surface of the solid carrier, an amylase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, a protective layer to protect the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof by embedding the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.
Resumen de: AU2024282877A1
An antibacterial nanoparticle comprising an inner silica core; a gold (Au) nanosphere surrounding the inner silica core; a surface layer comprising silver (Ag) surrounding the gold nanosphere or the silver is alloyed into the gold nanosphere; and an antimicrobial peptide conjugated to the surface layer, wherein the antimicrobial peptide is selected from the group consisting of a cysteine terminated Syn71 peptide, a cysteine terminated MC1-2 peptide, and a cysteine terminated Syn20 peptide.
Resumen de: MX2022013362A
The present application provides guide RNAs and genome-editing complexes or nanoparticles that are useful for specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease.
Resumen de: US20260015311A1
The present application relates to an amino lipid compound having the following structural formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and use thereof as a component of a lipid nanoparticle preparation for delivering a therapeutic agent. The present application further relates to a composition comprising the amino lipid compound, and particularly, to a lipid nanoparticle, and use thereof.
Resumen de: US20260015406A1
The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.
Resumen de: US20260015315A1
An amino lipid compound, a preparation method therefor, a composition thereof and an application thereof. Specifically disclosed are an amino lipid compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a use thereof in preparing a lipid nanoparticle for delivering an active ingredient, and a composition containing the amino lipid compound, especially a lipid nanoparticle, and a use thereof.
Resumen de: US20260015236A1
An amorphous carbon has a three-dimensional arrangement of carbon nanoparticles as agglomerates and is produced from carbon-containing raw materials by a charring and distillation process. The carbon is suitable for medical use, as thermal and/or refractory and/or radiation-resistant insulating material, as a filter element, as a storage element or for the production of plant products or for planting water-poor regions. In another aspect, an electric energy storage device in the form of a double-layer capacitor has a symmetrical structure, with a housing and a collector each from the outside inwards, with an electrode formed as a carbon layer and a separator with an electrolyte, wherein the carbon layer is formed as agglomerates from an amorphous carbon produced by the method for the material treatment of carbon-containing raw materials and having the structure of the three dimensional arrangement of carbon nanoparticles.
Resumen de: US20260015411A1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
Resumen de: US20260014251A1
Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable polynucleotide-containing formulations. In certain embodiments, compositions and methods are disclosed for creating thermostable polynucleotides and/or thermostable polynucleotides encoding at least one therapeutic agent for use in therapies for the treatment of health conditions in a subject. In some embodiments, compositions and methods are disclosed for creating thermostable polynucleotides for use in therapeutics, vaccines, and targeted gene therapies. In other embodiments, compositions and methods are disclosed for creating thermostable polynucleotides capable of being coated or encased for prolonged storage and/or timed-delivery.
Resumen de: US20260014124A1
Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
Resumen de: US20260014283A1
Provided herein are compositions comprising cells that each comprise at least one peptide-based nanoparticle. In some embodiments, the peptide-based nanoparticles each comprise a perfluorocarbon liquid core and a plurality of amphiphilic peptides surrounding the perfluorocarbon liquid core. Also provided herein are methods of preparing any of the compositions described herein, as well as methods of cellular tracking using any of the composition described herein.
Nº publicación: US20260014278A1 15/01/2026
Solicitante:
NUNTIUS THERAPEUTICS LTD [GB]
NUNTIUS THERAPEUTICS LIMITED
Resumen de: US20260014278A1
The present invention relates to compositions that can deliver therapeutic molecules such as nucleic acids to mammalian cells, and to the human and animal body and methods of preparing and using the same. The compositions comprise nanoparticles comprising a peptide dendrimer, a nucleic acid and a lipid. The compositions of the invention find utility in the field of medicine, such as for treating cancer and autoimmune diseases.
BOPI
Sede Electrónica
